Ruxolitinib cream (Opzelura) has just obtained reimbursement in France.
It will initially be direct access, that is to say that all dermatologists will be able to prescribe it
but it will have to be picked up initially from hospital pharmacies.

Numerous ongoing and future trials for diffuse vitiligo
(at least 5% of the face AND 5% of the body affected).